presentations Archives -

ASCO 2023 Conference Highlight: Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular Depot Injection of Abiraterone Decanoate, in Patients with Advanced Prostate Cancer

Propella Therapeutics, Inc. presented “Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular Depot Injection of Abiraterone Decanoate, in Patients with Advanced Prostate Cancer” at the American Society of Clinical Oncology Annual Meeting on June 3, 2023.

Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 16, 2023; San Francisco, CA): Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular Depot Injection of Abiraterone Decanoate in Patients with Advanced Prostate Cancer

Propella Therapeutics, Inc. presented “Phase 1/2a Study of PRL-02, a Long-Acting Intramuscular (IM) Depot Injection of Abiraterone Decanoate in Patients with Advanced Prostate Cancer” at the American Society of Clinical Oncology Genitourinary Symposium on February 16, 2023.

Presentation at the European Society for Medical Oncology Congress 2022 (September 11, 2022; Paris, France): Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)

Propella Therapeutics, Inc. presented phase 1/2 data of PRL-02 (a long-acting IM depot injection of abiraterone decanoate) for the treatment of advanced prostate cancer at the European Society for Medical Oncology Congress 2022 in Paris, France on September 11, 2022.

Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (PRL-02) – Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats

Propella Therapeutics, Inc. presented “Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA on February 17, 2022.

Presentation at the 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022): Propella Therapeutics Corporate Presentation

Propella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.

Presentation at the MedInvest Oncology Conference (December 7-10, 2021): Propella Therapeutics Corporate Presentation

Propella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.

Presentation at the American Society of Clinical Oncology Annual Meeting (June 4, 2021; San Francisco, CA): A Phase 1/2a, open-label, multicenter study of intramuscular abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114)

Propella Therapeutics, Inc. presented “A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)” at the American Society of Clinical Oncology Annual Meeting in San Francisco, CA on June 4, 2021.

Presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17, 2022; San Francisco, CA): Abiraterone decanoate (AD) – Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model

Propella Therapeutics, Inc. presented “Abiraterone decanoate (AD): Potent and long-acting activity of a novel intramuscular (IM) abiraterone prodrug depot in a castrate monkey model” at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA on February 11, 2021.

Presentation (Webinar, February 9, 2021): Capsaicin – The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target

Propella Therapeutics, Inc. presented a webinar titled “Capsaicin: The near perfect modulator of TRPV1, the ideal osteoarthritis (OA) pain target” on February 9, 2021.

Presentation at the 13th Annual Pain Therapeutics Summit (September 23, 2019; Washington, DC): A phase 2 double-blind clinical trial (VZU00025) to examine the tolerability, safety and effects of CGS-200-0 (Vehicle), CGS-200-1 (1% Capsaicin Topical Liquid) and CGS-200-5 (5% Capsaicin Topical Liquid) on osteoarthritis knee pain (OAKP)

Propella Therapeutics, Inc. presented the results of its completed Phase 2 double-blind clinical trial (which examined the tolerability, safety and effects of CGS-200-5 (5% capsaicin topical liquid) on osteoarthritis knee pain) at the 13th Annual Pain Therapeutics Summit in Washington, DC on September 23, 2019.